Ebanga™: The most recent FDA-approved drug for treating Ebola (pmc.ncbi.nlm.nih.gov)

• Ebanga (ansuvimab) is an FDA-approved monoclonal antibody for Ebola.
• Approval based on the PALM trial showing 28-day mortality of 35.1% with Ebanga.
• Ebanga is a single-dose therapy that significantly reduces mortality compared to ZMapp.

"The FDA has approved Ebanga (ansuvimab), a monoclonal antibody for treating Ebola virus disease. Clinical trials showed a significant reduction in mortality compared to standard care. The approval is based on the PALM trial in the Democratic Republic of Congo, where patients receiving Ebanga had a survival rate of 89.3%. Ebanga neutralizes the Ebola virus and is administered intravenously. This approval expands therapeutic options and supports outbreak response, especially in resource-limited settings where early treatment is critical."